First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.

@article{Starodub2015FirstinHumanTO,
  title={First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.},
  author={Alexander N. Starodub and Allyson J. Ocean and Manish Shah and Michael J Guarino and Vincent J. Picozzi and Linda T. Vahdat and Sajeve S. Thomas and Serengulam V. Govindan and Pius P Maliakal and William A. Wegener and Steven A Hamburger and Robert M Sharkey and David M. Goldenberg},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 17},
  pages={3870-8}
}
PURPOSE Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the active metabolite of irinotecan. This phase I trial evaluated this ADC as a potential therapeutic for pretreated patients with a variety of metastatic solid cancers. EXPERIMENTAL DESIGN Sacituzumab govitecan was administered on days 1 and 8 of 21-day cycles, with cycles repeated until dose-limiting toxicity or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
20 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers

  • DM Goldenberg, EA Rossi, SV Govindan, TM Cardillo, McBrideWJ, M Zalath
  • J Clin Oncol
  • 2014
Highly Influential
10 Excerpts

Specificity andproperties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody

  • SteinR, BasuA, ChenS, LB Shih, GoldenbergDM
  • Int J Cancer 1993;55:938–46
  • 1993
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…